## Abstract We assessed the status of dopamine nerve terminals in patients treated with dopamine receptor blocking agents (DRBAs) who had developed drug‐induced parkinsonism (DIP). We performed [^123^I]FP‐CIT SPET in 32 consecutive patients who were on DRBAs for at least 6 months and developed extr
[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease
✍ Scribed by Mordechai Lorberboym; Therese A. Treves; Eldad Melamed; Yair Lampl; Mark Hellmann; Ruth Djaldetti
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 58 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Parkinsonism in patients taking neuroleptic medications might be induced by dopamine receptor blockade alone or by dopamine blockade with nigrostriatal dysfunction. The differentiation between Parkinson's disease (PD) and drug‐induced parkinsonism (DIP) is difficult to assess on clinical grounds alone. In this study, we have evaluated the clinical characteristics and striatal binding of ^123^I‐FP‐CIT (N‐ω‐fluoropropyl‐2β‐carboxymethoxy‐3β‐{4‐iodophenyl}tropane) in patients who developed DIP. A total of 20 patients (mean age, 62 ± 13 years) who developed parkinsonism while on neuroleptic agents and 10 age‐matched controls were enrolled. [123]‐FP‐CIT single‐photon emission computed tomography (SPECT) was performed in all subjects. Neurological assessment was performed with the Motor part of the Unified Parkinson's Disease Rating Scale. [123]‐FP‐CIT binding of the entire striatum, caudate, and putamen was calculated. Patients were divided into two subgroups according to SPECT results for comparison of clinical characteristics. There were 9 patients who had normal scans and 11 who showed significantly diminished striatal binding, suggesting degeneration of the nigrostriatal system. Subanalyses of abnormal scans revealed significantly diminished binding in the caudate (P < 0.001 for right and left caudate) and putamen (P = 0.002 and P < 0.05 for right and left putamen, respectively). There were no differences in clinical features between patients with normal and abnormal scans. Symptoms included asymmetric tremor, bradykinesia, and rigidity in both groups. Freezing gait was present in two patients with normal scans. These results indicate that DIP is clinically indistinguishable from PD. Brain imaging with FP‐CIT helps to determine whether DIP is entirely drug‐induced or an exacerbation of subclinical PD. © 2005 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract There is substantial evidence to support a role for small vessel disease (SVD) as a cause for vascular parkinsonism (VP). Using [^123^I] FP‐CIT SPECT (single photon emission computed tomography), we have tried to determine whether VP patients have pre‐synaptic dopaminergic function simi
The variability in clinical features and the masking effects of drug therapy in Parkinson's disease (PD) can affect clinical assessment of disease severity. The aim of this study was to assess the imaging of dopamine transporters using 123 I-FP-CIT SPECT and its correlation with disease staging, sev
## Abstract We aimed to investigate the accuracy of transcranial brain parenchyma sonography (TCS) for differentiation between idiopathic Parkinson's disease (PD) and essential tremor (ET) in comparison to ^123^I‐FP‐CIT SPECT (FP‐CIT SPECT). Seventy‐four patients, in whom PD or ET was suspected on
## Abstract To unveil cognitive‐nigrostriatal correlations in Parkinson's disease (PD), 30 de novo, drug‐naïve PD patients and 15 patients with essential tremor (Controls, CTR) underwent a neuropsychological (NPS) battery and brain SPECT with [I‐123]Ioflupane, as a biomarker of nigrostriatal functi
## Abstract Economic evaluation (Italian NHS perspective) modeling ^123^I‐FP‐CIT SPECT (DaTSCAN®) compared to clinical judgment alone for differentiating essential tremor (ET) from Parkinson's Disease (PD). A 5‐year Markov model was constructed to assess the cost‐effectiveness of ^123^I‐FP‐CIT SPEC